
Camil Castelo Branco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7114293/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	High persistence in Spanish transgender minors: 18 years of experience of the Gender Identity Unit of Catalonia. Revista De PsiquiatrÃa Y Salud Mental, 2024, 17, 35-40.	1.8	7
2	Vaginal laser therapy for genitourinary syndrome of menopause – systematic review. Maturitas, 2022, 156, 37-59.	2.4	23
3	Weight gain in menopause: systematic review of adverse events in women treated with black cohosh. Climacteric, 2022, 25, 220-227.	2.4	3
4	Pre-induction cervical ripening with different initial doses of intravaginal misoprostol: time to delivery and peri-natal outcomes. Journal of Obstetrics and Gynaecology, 2022, 42, 1112-1116.	0.9	1
5	Assessment of Quality of Life, Sexual Quality of Life, and Pain Symptoms in Deep Infiltrating Endometriosis Patients with or Without Associated Adenomyosis and the Influence of a Flexible Extended Combined Oral Contraceptive Regimen: Results of a Prospective, Observational Study. Journal of Sexual Medicine, 2022, 19, 311-318.	0.6	18
6	Two Sisters with Kallmann Syndrome, Gonadal Dysgenesis, and Multiple Neuromuscular and Endocrine Disorders: Report of Two Cases with Description of an Unusual Association. Reproductive Sciences, 2022, , 1.	2.5	0
7	Intravaginal misoprostol versus uterine curettage for missed abortion: A costâ€effectiveness analysis. Journal of Obstetrics and Gynaecology Research, 2022, , .	1.3	2
8	Safety of prasterone in breast cancer survivors treated with aromatase inhibitors: the VIBRA pilot study. Climacteric, 2022, 25, 476-482.	2.4	7
9	Black cohosh efficacy and safety for menopausal symptoms. The Spanish Menopause Society statement. Gynecological Endocrinology, 2022, 38, 379-384.	1.7	3
10	Are anthropometric data a tool for determining the severity of OHSS? Yes, it could be!. BMC Women's Health, 2022, 22, 155.	2.0	0
11	Sexual Function in Breast Cancer Patients: A Review of the Literature. Clinical and Experimental Obstetrics and Gynecology, 2022, 49, 134.	0.2	5
12	Physiology of intraâ€abdominal volume during pregnancy. Journal of Obstetrics and Gynaecology, 2021, 41, 1016-1022.	0.9	10
13	Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms – an update on the evidence. Climacteric, 2021, 24, 109-119.	2.4	22
14	Diagnosis and Surgical Treatment of Uterine Isthmus Atresia: A Case Report and Review of the Literature. Journal of Minimally Invasive Gynecology, 2021, 28, 137-141.	0.6	2
15	Genitourinary Syndrome of Menopause: Current Treatment Options in Breast Cancer Survivors – Systematic Review. Maturitas, 2021, 143, 47-58.	2.4	27
16	Quality of Life in Infertile Women with Polycystic Ovary Syndrome: a Comparative Study. Reproductive Sciences, 2021, 28, 1901-1909.	2.5	14
17	Assessing the Usefulness of Severity Markers in Women with Ovarian Hyperstimulation Syndrome. Reproductive Sciences, 2021, 28, 1041-1048.	2.5	2
18	Genitourinary syndrome of menopause assessment tools. Journal of Mid-Life Health, 2021, 12, 99.	0.6	8

#	Article	IF	CITATIONS
19	Psychological Issues and Sexual Function in Women with Different Infertility Causes: Focus on Polycystic Ovary Syndrome. Reproductive Sciences, 2021, 28, 2830-2838.	2.5	15
20	Prasterona en el tratamiento del sÃndrome genitourinario de la menopausia. Clinica E Investigacion En Ginecologia Y Obstetricia, 2021, 48, 67.	0.1	0
21	The results of different labour induction approaches: A Cross sectional study. Obstetrics & Gynecology International Journal, 2021, 12, 108-111.	0.1	1
22	Psychopathological symptoms in Spanish subjects with gender dysphoria. A cross-sectional study. Gynecological Endocrinology, 2021, 37, 534-540.	1.7	2
23	Effects of anthropometric parameters on bone mineral density in women: from perimenopause to old age. Gynecological Endocrinology, 2021, 37, 902-905.	1.7	Ο
24	Current lifestyle and exclusive breastfeeding: an impossible balance?. Journal of Obstetrics and Gynaecology, 2021, , 1-4.	0.9	0
25	Management of symptomatic uterine fibroids after ulipristal acetate suspension and identification of high risk patients for surgery at 6-months of follow-up. Gynecological Endocrinology, 2021, 37, 831-835.	1.7	2
26	Long-term Follow-up of Sexual Quality of Life after Laparoscopic Surgery in Patients with Deep Infiltrating Endometriosis. Journal of Minimally Invasive Gynecology, 2021, 28, 1912-1919.	0.6	15
27	Are we assessing genitourinary syndrome of menopause properly?. Climacteric, 2021, 24, 529-530.	2.4	3
28	Quality of life and sexual function in women with polycystic ovary syndrome: a comprehensive review. Gynecological Endocrinology, 2020, 36, 96-103.	1.7	23
29	Alternative strategies for the management of ovarian hyperstimulation syndrome, the role of intra-abdominal hypertension control. Gynecological Endocrinology, 2020, 36, 197-203.	1.7	3
30	Use of Radioactive Seed Localization to Guide Removal of a Nonpalpable Endometriotic Lesion: A Case Report. Journal of Minimally Invasive Gynecology, 2020, 27, 551-554.	0.6	0
31	Efficacy and safety of ossein-hydroxyapatite complex versus calcium carbonate to prevent bone loss. Climacteric, 2020, 23, 252-258.	2.4	8
32	Gender differences in the prevalence of vitamin D deficiency in a southern Latin American country: a pilot study. Climacteric, 2020, 23, 410-416.	2.4	17
33	Changes in bone mass and body composition after bariatric surgery. Gynecological Endocrinology, 2020, 36, 578-581.	1.7	9
34	Management of Transsexuality in anÂOutpatient Gynecologic Area. ISGE Series, 2019, , 155-166.	0.2	0
35	Urinary incontinence in climacteric afrodescendant women from the Colombian Caribbean. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2019, 8, 3817.	0.1	0
36	Impact Of Vulvovaginal Atrophy Of Menopause In Spanish Women: Prevalence And Symptoms According To The EVES Study. Sexual Medicine, 2019, 7, 207-216.	1.6	9

#	Article	IF	CITATIONS
37	Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women. Maturitas, 2019, 124, 55-61.	2.4	41
38	Ovarian hyperstimulation syndrome. A new look at an old problem. Gynecological Endocrinology, 2019, 35, 651-656.	1.7	13
39	Sleep quality and related factors in postmenopausal women. Maturitas, 2019, 123, 73-77.	2.4	22
40	Turner Syndrome: Primary Amenorrhea from Adolescence to Aging. , 2019, , 19-32.		0
41	Anterior abdominal wall parasitic leiomyoma: case report. Gynecological Endocrinology, 2018, 34, 103-106.	1.7	4
42	Current treatment options for postmenopausal vaginal atrophy. International Journal of Women's Health, 2018, Volume 10, 387-395.	2.6	81
43	Vulvar and vaginal atrophy as viewed by the Spanish REVIVE participants: symptoms, management and treatment perceptions. Climacteric, 2017, 20, 55-61.	2.4	32
44	Local hormone therapy for genitourinary syndrome of menopause in breast cancer patients: is it safe?. Gynecological Endocrinology, 2017, 33, 418-420.	1.7	12
45	Use of hormone therapy for menopausal symptoms and quality of life in breast cancer survivors. Safe and ethical?. Gynecological Endocrinology, 2017, 33, 10-15.	1.7	7
46	A trial of oral nifedipine and oral labetalol in preeclampsia hypertensive emergency treatment. Journal of Obstetrics and Gynaecology, 2017, 37, 864-866.	0.9	4
47	Hidradenoma papilliferum of the vulva in a postpartum woman: A case report. Journal of Obstetrics and Gynaecology, 2017, 37, 683-684.	0.9	7
48	Vaginal misoprostol and cervical ripening balloon for induction of labor in lateâ€ŧerm pregnancies. Journal of Obstetrics and Gynaecology Research, 2017, 43, 87-91.	1.3	5
49	Efficacy and safety of misoprostol, dinoprostone and Cook's balloon for labour induction in women with foetal growth restriction at term. Archives of Gynecology and Obstetrics, 2017, 296, 777-781.	1.7	25
50	What can we do to reduce the associated costs in induction of labour of intrauterine growth restriction foetuses at term? A cost-analysis study. Archives of Gynecology and Obstetrics, 2017, 296, 483-488.	1.7	10
51	Complementary and Alternative Therapies for Menopausal Vasomotor Symptoms. , 2017, , 261-272.		Ο
52	Induction of Labour: Eternal Controversy. International Journal of Pregnancy & Child Birth, 2017, 3, .	0.1	0
53	Long-term satisfaction and tolerability with low-dose flutamide: a 20-year surveillance study on 120 hyperandrogenic women. Gynecological Endocrinology, 2016, 32, 723-727.	1.7	3
54	Cardiovascular risk in climacteric women: focus on diet. Climacteric, 2016, 19, 215-221.	2.4	3

4

#	Article	IF	CITATIONS
55	Controversies over the use of GnRH agonists for reduction of chemotherapy-induced gonadotoxicity. Climacteric, 2016, 19, 522-525.	2.4	11
56	Sexuality and quality of life in congenital hypogonadisms. Gynecological Endocrinology, 2016, 32, 947-950.	1.7	11
57	Outpatient hysteroscopic polypectomy: bipolar energy system (Versapoint®) versus diode laser – randomized clinical trial. Gynecological Endocrinology, 2016, 32, 196-200.	1.7	17
58	2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric, 2016, 19, 109-150.	2.4	676
59	Supplementation during pregnancy: beliefs and science. Gynecological Endocrinology, 2016, 32, 509-516.	1.7	52
60	Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy. Climacteric, 2016, 19, 60-65.	2.4	25
61	Pituitary-ovary axis and ovarian reserve in fertile women with multiple sclerosis: A pilot study. Multiple Sclerosis Journal, 2016, 22, 564-568.	3.0	36
62	Essure a novel option for the treatment of hydrosalpinx: a case series and literature review. Gynecological Endocrinology, 2016, 32, 166-170.	1.7	7
63	Early menopause: A hazard to a woman's health. Indian Journal of Medical Research, 2016, 143, 420.	1.0	37
64	Senshio®, a new oral treatment for VVA. Maturitas, 2015, 82, 321-322.	2.4	0
65	iContraception®: a software tool to assist professionals in choosing contraceptive methods according to WHO medical eligibility criteria. Journal of Family Planning and Reproductive Health Care, 2015, 41, 142-145.	0.8	4
66	Update on management of genitourinary syndrome of menopause: A practical guide. Maturitas, 2015, 82, 308-313.	2.4	111
67	The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric, 2015, 18, 233-240.	2.4	40
68	Comparison of the effects of calcium carbonate and ossein–hydroxyapatite complex on back and knee pain and quality of life in osteopenic perimenopausal women. Maturitas, 2015, 81, 76-82.	2.4	3
69	Characteristics of post-menopausal women with genitourinary syndrome of menopause: Implications for vulvovaginal atrophy diagnosis and treatment selection. Maturitas, 2015, 81, 462-469.	2.4	33
70	Use of ossein–hydroxyapatite complex in the prevention of bone loss: a review. Climacteric, 2015, 18, 29-37.	2.4	7
71	Calcium-collagen chelate supplementation reduces bone loss in osteopenic postmenopausal women. Climacteric, 2015, 18, 105-6.	2.4	1
72	Hyperandrogenism in post-menopausal women: a diagnosis challenge. Gynecological Endocrinology, 2014, 30, 23-25.	1.7	9

#	Article	IF	CITATIONS
73	Comparative cytogenetic analysis in two tissues with different lineage in Turner's syndrome patients: correlation with phenotype. Gynecological Endocrinology, 2014, 30, 282-286.	1.7	4
74	Alcohol and drug abuse and risky sexual behaviours in young adult women. Gynecological Endocrinology, 2014, 30, 581-586.	1.7	8
75	Hearing loss in adult women with Turner's syndrome and other congenital hypogonadisms. Gynecological Endocrinology, 2014, 30, 111-116.	1.7	9
76	Long-term effect of hormone therapy on bone in early menopause: vertebral fractures after 20 years. Climacteric, 2014, 17, 336-341.	2.4	3
77	Essure [®] and chronic pelvic pain: A population-based cohort. Journal of Obstetrics and Gynaecology, 2014, 34, 712-713.	0.9	40
78	Effects of a 12-month multi-component exercise program on the body composition of postmenopausal women. Climacteric, 2014, 17, 155-163.	2.4	16
79	Luteal phase support with progesterone in intrauterine insemination: a prospective randomized study. Gynecological Endocrinology, 2014, 30, 197-201.	1.7	22
80	The immune system and aging: a review. Gynecological Endocrinology, 2014, 30, 16-22.	1.7	321
81	Management of Turner syndrome in adult life and beyond. Maturitas, 2014, 79, 471-475.	2.4	10
82	Spanish consensus on sexual health in men and women over 50. Maturitas, 2014, 78, 138-145.	2.4	17
83	Adolescent Pregnancy in Portugal. , 2014, , 523-534.		0
84	Teenage Pregnancy in Argentina: A Reality. , 2014, , 171-189.		1
85	Phytoestrogens and bone health at different reproductive stages. Gynecological Endocrinology, 2013, 29, 735-743.	1.7	27
86	Turner's syndrome and other forms of congenital hypogonadism impair quality of life and sexual function. American Journal of Obstetrics and Gynecology, 2013, 208, 484.e1-484.e6.	1.3	32
87	Efficacy of Essure hysteroscopic sterilization – 5 years follow up of 1200 women. Gynecological Endocrinology, 2013, 29, 580-582.	1.7	40
88	Early prophylactic treatment in pregnant women during the 2009–2010 H1N1 pandemic: Obstetric and neonatal outcomes. Journal of Obstetrics and Gynaecology, 2013, 33, 128-134.	0.9	12
89	Panoramic radiomorphometry and vertebral fractures in Spanish postmenopausal women. Maturitas, 2013, 76, 364-369.	2.4	7
90	Fracturas vertebrales tras tratamiento hormonal en la menopausia: 20 años de seguimiento. Progresos En Obstetricia Y Ginecologia, 2013, 56, 462-466.	0.0	0

#	Article	IF	CITATIONS
91	Position of the Spanish Menopause Society regarding the management of menopausal symptoms in breast cancer patients. Maturitas, 2013, 75, 294-300.	2.4	15
92	Tolerability of different oral iron supplements: a systematic review. Current Medical Research and Opinion, 2013, 29, 291-303.	1.9	233
93	Revisiting lactic acidosis in an HIV-1 infected pregnant woman on antiretroviral therapy. Journal of Obstetrics and Gynaecology, 2013, 33, 310-311.	0.9	1
94	Osteoporosis, fragility fracture, and periodontal disease. Menopause, 2013, 20, 79-84.	2.0	14
95	Management of Turner's syndrome in adult life: case-series and systematic review. Gynecological Endocrinology, 2012, 28, 726-732.	1.7	7
96	Continuation Rate of Combined Hormonal Contraception: A Prospective Multicenter Study. Journal of Women's Health, 2012, 21, 490-495.	3.3	15
97	Climacteric. Climacteric, 2012, 15, 500-510.	2.4	1
98	Climacteric Commentaries. Climacteric, 2012, 15, 95-102.	2.4	0
99	Recomendaciones sobre ranelato de estroncio en el tratamiento de la osteoporosis. Progresos En Obstetricia Y Ginecologia, 2012, 55, 38-49.	0.0	0
100	Evidence-based assessment of the impact of the WHI on women's health. Climacteric, 2012, 15, 281-287.	2.4	53
101	Recomendaciones de la Sociedad Española de GinecologÃa y Obstetricia sobre la prevención y el tratamiento de la atrofia vaginal. Progresos En Obstetricia Y Ginecologia, 2012, 55, 408-415.	0.0	2
102	Loss of smell but not taste in adult women with Turner's syndrome and other congenital hypogonadisms. Maturitas, 2012, 73, 244-250.	2.4	15
103	M234 INCIDENCE OF ADVERSE EFFECTS IN FOUR ORAL IRON FORMULATIONS: A SYSTEMATIC REVIEW. International Journal of Gynecology and Obstetrics, 2012, 119, S607.	2.3	0
104	Understanding weight gain at menopause. Climacteric, 2012, 15, 419-429.	2.4	430
105	Complications of hysteroscopic Essure [®] sterilisation: report on 4306 procedures performed in a single centre. BJOG: an International Journal of Obstetrics and Gynaecology, 2012, 119, 795-799.	2.3	91
106	The effect of different hormone therapies on anti-müllerian hormone serum levels in anovulatory women of reproductive age. Gynecological Endocrinology, 2011, 27, 216-224.	1.7	26
107	Optimizing soy isoflavones effect in postmenopausal women: the impact of timing on climacteric symptoms. Gynecological Endocrinology, 2011, 27, 696-700.	1.7	6
108	Isoflavones: effects on bone health. Climacteric, 2011, 14, 204-211.	2.4	30

#	Article	IF	CITATIONS
109	Pregnancy following radical vulvectomy for carcinoma of the vulva: a case report and literature review. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2011, 158, 113-114.	1.1	4
110	Statins and cancer: Harmful or helpful?. Maturitas, 2011, 68, 198.	2.4	1
111	Effects of body composition and menopause characteristics on maximal oxygen uptake of postmenopausal women. Menopause, 2011, 18, 1191-1197.	2.0	8
112	Climacteric Commentaries. Climacteric, 2011, 14, 689-695.	2.4	0
113	Further data favouring hormonal dependency of cerebral meningiomas: evidence from a patient treated with cabergoline. Gynecological Endocrinology, 2011, 27, 134-137.	1.7	4
114	Do Patients Lie? An Open Interview vs. a Blind Questionnaire on Sexuality. Journal of Sexual Medicine, 2010, 7, 873-880.	0.6	10
115	Periodontitis and osteoporosis: a systematic review. Climacteric, 2010, 13, 523-529.	2.4	92
116	Treatment persistence and compliance with a combination of calcium and vitamin D. Climacteric, 2010, 13, 578-584.	2.4	32
117	Quality of Life after Laparoscopic Excision of Rectovaginal Endometriosis: Results of a Pilot Study. Journal of Minimally Invasive Gynecology, 2010, 17, S135.	0.6	0
118	Analysis of the Risk Factors of Complication and Conversion in Laparoscopic Myomectomies. Journal of Minimally Invasive Gynecology, 2010, 17, S145.	0.6	0
119	Menopause and aging: Changes in the immune system—A review. Maturitas, 2010, 67, 316-320.	2.4	198
120	Unintended pregnancy after long-term Essure microinserts placement. Fertility and Sterility, 2010, 94, 2793-2795.	1.0	5
121	Quality of Sex Life after Laparoscopic Treatment of Rectovaginal Endometriosis: Results of a Pilot Study. Journal of Minimally Invasive Gynecology, 2010, 17, S135.	0.6	0
122	Comprehensive clinical management of hirsutism. Gynecological Endocrinology, 2010, 26, 484-493.	1.7	44
123	The role of intranasal estradiol spray in the management of moderate to severe vasomotor symptoms in menopausal women. Gynecological Endocrinology, 2010, 26, 23-29.	1.7	6
124	Atherogenic metabolic profile in PCOS patients: role of obesity and hyperandrogenism. Gynecological Endocrinology, 2010, 26, 736-742.	1.7	44
125	Contraception knowledge and sexual behaviour in secondary school students. Gynecological Endocrinology, 2010, 26, 479-483.	1.7	8
126	Therapeutic options for postmenopausal female sexual dysfunction. Climacteric, 2010, 13, 103-120.	2.4	65

#	Article	IF	CITATIONS
127	Prevalence and risk factors for sexual dysfunction in gynecologic tumors survivors Journal of Clinical Oncology, 2010, 28, e19622-e19622.	1.6	Ο
128	Female contraception over 40. Human Reproduction Update, 2009, 15, 599-612.	10.8	40
129	The relationships between mercury and selenium in plankton and fish from a tropical food web. Environmental Science and Pollution Research, 2009, 16, 10-24.	5.3	67
130	Long-term safety and tolerability of flutamide for the treatment of hirsutism. Fertility and Sterility, 2009, 91, 1183-1188.	1.0	24
131	Impact of anthropometric parameters on quality of life during menopause. Fertility and Sterility, 2009, 92, 1947-1952.	1.0	18
132	Unintended pregnancy after gonadal failure chemoprevention with gonadotropin-releasing hormone agonist in women with hematologic malignancies. Fertility and Sterility, 2009, 92, 1260-1263.	1.0	2
133	Ovarian hyperstimulation, hyperprolactinaemia and LH gonadotroph adenoma. Reproductive BioMedicine Online, 2009, 19, 153-155.	2.4	25
134	Hepatotoxicity during low-dose flutamide treatment for hirsutism. Gynecological Endocrinology, 2009, 25, 419-422.	1.7	18
135	Comparison of a New Reusable Gynecologic Laparoscopic Electric Morcellator with a Disposable Morcellator: a Preliminary Trial. Journal of Minimally Invasive Gynecology, 2009, 16, 595-598.	0.6	8
136	Risk of hypoactive sexual desire disorder and associated factors in a cohort of oophorectomized women. Climacteric, 2009, 12, 525-532.	2.4	18
137	Effect of specific exercise training on bone mineral density in women with postmenopausal osteopenia or osteoporosis. Gynecological Endocrinology, 2009, 25, 616-620.	1.7	33
138	Posicionamiento de la Asociación Española para el Estudio de la Menopausia sobre el uso clÃnico de la CimicÃfuga racemosa en el climaterio. Progresos En Obstetricia Y Ginecologia, 2009, 52, 712-721.	0.0	2
139	CLINICAL ASPECTS AND RELATIONSHIPS BETWEEN WEIGHT GAIN, OBESITY AND MENOPAUSE. Maturitas, 2009, 63, S19.	2.4	2
140	QUALITY OF LIFE, CLINICAL ASPECTS AND RELATIONSHIPS BETWEEN OBESITY AND MENOPAUSE. Maturitas, 2009, 63, S56.	2.4	0
141	Efficacy of ossein-hydroxyapatite complex compared with calcium carbonate to prevent bone loss. Menopause, 2009, 16, 984-991.	2.0	11
142	Long-Term Safety and Tolerability of Flutamide for the Treatment of Hirsutism. Obstetrical and Gynecological Survey, 2009, 64, 598-599.	0.4	0
143	Cardiovascular Risk During the Menopause. Vascular Disease Prevention, 2009, 6, 103-108.	0.2	0
144	Definition and diagnosis of sexuality in the XXI century. Maturitas, 2008, 60, 50-58.	2.4	19

#	Article	IF	CITATIONS
145	Educational and organizational interventions used to improve the knowledge of metabolic syndrome among postmenopausal women. Fertility and Sterility, 2008, 90, 444-446.	1.0	4
146	Satisfaction and tolerance with office hysteroscopic tubal sterilization. Fertility and Sterility, 2008, 90, 1182-1186.	1.0	105
147	Follicle-stimulating hormone does not directly regulate bone mass in human beings: evidence from nature. Fertility and Sterility, 2008, 90, 2211-2216.	1.0	11
148	Women's perception of the efficacy of a soy extract with probiotic: The M3 study. Gynecological Endocrinology, 2008, 24, 178-183.	1.7	16
149	Hormone therapy for the management of the menopause in Ecuador: Perception, use and knowledge among middle-aged women. Gynecological Endocrinology, 2008, 24, 580-585.	1.7	6
150	Effect of androgens combined with hormone therapy on quality of life in post-menopausal women with sexual dysfunction. Gynecological Endocrinology, 2008, 24, 691-695.	1.7	22
151	Impact of diabetes mellitus on the sexuality of Peruvian postmenopausal. Gynecological Endocrinology, 2008, 24, 470-474.	1.7	50
152	Compounds for the treatment of atropic vaginitis. Expert Opinion on Therapeutic Patents, 2008, 18, 1385-1394.	5.0	5
153	Understanding how personality factors may influence quality of life. Menopause, 2008, 15, 914-918.	2.0	22
154	Effect of Androgenic and Antiandrogenic Acting Compounds in Macrophage Accumulation and Cell Replication in the Aorta of Oophorectomized Hypercholesterolemic Rabbits. Vascular Disease Prevention, 2008, 3, 369-374.	0.2	0
155	The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III): prevalence of the metabolic syndrome in postmenopausal Latin American women. Climacteric, 2007, 10, 164-170.	2.4	91
156	Female sexual dysfunction in postmenopausal women. Expert Opinion on Therapeutic Patents, 2007, 17, 639-647.	5.0	18
157	Pain in fibromyalgia patients. Therapy: Open Access in Clinical Medicine, 2007, 4, 193-200.	0.2	Ο
158	Treatment of atrophic vaginitis. Therapy: Open Access in Clinical Medicine, 2007, 4, 349-353.	0.2	7
159	Use of gonadotropin-releasing hormone agonists in patients with Hodgkin's disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy. Fertility and Sterility, 2007, 87, 702-705.	1.0	50
160	Effects on serum lipid and leptin levels of three different doses of norethisterone continuously combined with a fixed dose of 17β-estradiol for nasal administration in postmenopausal women: a controlled, double-blind study. Fertility and Sterility, 2007, 88, 383-389.	1.0	12
161	Spanish post-menopausal women's viewpoints on hormone therapy. Maturitas, 2007, 56, 420-428.	2.4	23
162	Influence of high-intensity training and of dietetic and anthropometric factors on menstrual cycle disorders in ballet dancers. Gynecological Endocrinology, 2006, 22, 31-35.	1.7	52

#	Article	IF	CITATIONS
163	The prescription of hormone replacement therapy in Spain: Differences between general practitioners and gynaecologists. Maturitas, 2006, 55, 308-316.	2.4	16
164	Age at menopause in Latin America. Menopause, 2006, 13, 706-712.	2.0	105
165	Stress symptoms and burnout in obstetric and gynaecology residents. BJOG: an International Journal of Obstetrics and Gynaecology, 2006, 114, 94-98.	2.3	70
166	Effect of a compound containing isoflavones, primrose oil and vitamin E in two different doses on climacteric symptoms. Journal of Obstetrics and Gynaecology, 2006, 26, 344-347.	0.9	4
167	Sexual dysfunction and related risk factors in a cohort of middle-aged Ecuadorian women. Journal of Obstetrics and Gynaecology, 2006, 26, 682-686.	0.9	38
168	The dilemma of menopause and hormone replacement – a challenge for women and health-care providers: knowledge of menopause and hormone therapy in Spanish menopausal women. Climacteric, 2006, 9, 380-387.	2.4	13
169	Different Lifestyles in Young Women From Urban and Rural Areas May Explain Different Cardiovascular Risk. Vascular Disease Prevention, 2006, 3, 79-82.	0.2	1
170	Management of menopause. Minerva Ginecologica, 2006, 58, 137-52.	0.8	12
171	Changes in bone turnover markers after calcium-enriched milk supplementation in healthy postmenopausal women: a randomized, double-blind, prospective clinical trial. Menopause, 2005, 12, 63-68.	2.0	25
172	Hiperandrogenismo ovárico. Valoración clÃnica y terapéutica. Clinica E Investigacion En Ginecologia Y Obstetricia, 2005, 32, 244-256.	0.1	0
173	Vascular reactivity and atheromatous plaques in post-menopausal women on tibolone treatment. Maturitas, 2005, 50, 259-265.	2.4	16
174	Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy. Maturitas, 2005, 50, 98-104.	2.4	53
175	Menopausal transition in Movima women, a Bolivian native-American. Maturitas, 2005, 51, 380-385.	2.4	30
176	Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas, 2005, 52, 46-52.	2.4	223
177	Available medical choices for the management of menopause. Maturitas, 2005, 52, 61-70.	2.4	13
178	Management of osteoporosis in general practice: a cross-sectional survey of primary care practitioners in Spain. Osteoporosis International, 2004, 15, 252-257.	3.1	30
179	Raloxifene inhibits cholesterol aortic content but not atherosclerotic plaque size in oophorectomised cholesterol-fed rabbits. Journal of Obstetrics and Gynaecology, 2004, 24, 47-51.	0.9	7
180	Efficacy and Safety of Ibuprofen Arginine in the Treatment of Primary Dysmenorrhoea. Clinical Drug Investigation, 2004, 24, 385-393.	2.2	6

#	Article	IF	CITATIONS
181	Terapia hormonal sustitutiva a bajas dosis. Clinica E Investigacion En Ginecologia Y Obstetricia, 2004, 31, 161-168.	0.1	Ο
182	Operación de Vecchietti por laparoscopia para la creación de una neovagina en el sÃndrome de Mayer-Rokitansky-Kuster-Hauser. Evaluación anatomicofuncional. Progresos En Obstetricia Y Ginecologia, 2004, 47, 367-372.	0.0	1
183	Influence of psycho-social factors on climacteric symptoms. Maturitas, 2004, 48, 425-431.	2.4	79
184	Relationship between psychological complaints and vasomotor symptoms during climacteric. Maturitas, 2004, 49, 205-210.	2.4	64
185	Impairment of sexual activity in middle-aged women in Chile. Menopause, 2004, 11, 78-81.	2.0	51
186	Patients' and clinicians' attitudes after the Women's Health Initiative study. Menopause, 2004, 11, 57-61.	2.0	76
187	Calidad de vida relacionada con la salud en la mujer española durante la perimenopausia y posmenopausia. Desarrollo y validación de la Escala Cervantes. Medicina ClÃnica, 2004, 122, 205-211.	0.6	12
188	Secreting ovarian tumors may protect women from osteoporosis. Gynecologic Oncology, 2003, 88, 149-152.	1.4	27
189	Piel y menopausia: influencia de los estrógenos y del tratamiento hormonal sustitutivo en el envejecimiento cutáneo. Piel, 2003, 18, 153-159.	0.0	0
190	Effects of estradiol, cyproterone acetate, tibolone and raloxifene on uterus and aorta atherosclerosis in oophorectomized cholesterol-fed rabbits. Maturitas, 2003, 45, 59-66.	2.4	7
191	Age, menopause and hormone replacement therapy influences on cardiovascular risk factors in a cohort of middle-aged Chilean women. Maturitas, 2003, 45, 205-212.	2.4	30
192	Effects of transdermal estrogens on endothelial function in postmenopausal women with coronary disease. Climacteric, 2003, 6, 38-44.	2.4	14
193	Prevalence of sexual dysfunction in a cohort of middle-aged women: influences of menopause and hormone replacement therapy. Journal of Obstetrics and Gynaecology, 2003, 23, 426-430.	0.9	104
194	Alendronate daily, weekly in conventional tablets and weekly in enteric tablets: preliminary study on the effects in bone turnover markers and incidence of side effects. Journal of Obstetrics and Gynaecology, 2003, 23, 278-281.	0.9	7
195	Influences of hormone replacement therapy on postmenopausal women's health perceptions. Menopause, 2003, 10, 235-240.	2.0	22
196	Tibolone and risk of endometrial polyps: a prospective, comparative study with hormone therapy. Menopause, 2003, 10, 534-537.	2.0	16
197	Effects of transdermal estrogens on endothelial function in postmenopausal women with coronary disease. Climacteric, 2003, 6, 38-44.	2.4	2
198	Tibolone inhibits aortic atherosclerotic lesionformation in oophorectomized cholesterol-fed rabbits. Experimental and Clinical Cardiology, 2003, 8, 21-5.	1.3	0

#	Article	IF	CITATIONS
199	Effects of transdermal estrogens on endothelial function in postmenopausal women with coronary disease. Climacteric, 2003, 6, 38-44.	2.4	3
200	Cyproterone acetate could counteract the benefits of estradiol valerate in oophorectomized cholesterol-fed rabbits. Menopause, 2002, 9, 282-287.	2.0	2
201	Use of hormone replacement therapy among Chilean women: a comparison between socioeconomic levels. Menopause, 2002, 9, 377-380.	2.0	22
202	Efficacy and safety of a phytoestrogen preparation derived from Glycine max (L.) Merr in climacteric symptomatology: A multicentric, open, prospective and non-randomized trial. Phytomedicine, 2002, 9, 85-92.	5.3	46
203	Evaluación clÃnica y terapéutica del hirsutismo. Piel, 2002, 17, 428-436.	0.0	1
204	Paradoxical Effect After IPL Photoepilation. Dermatologic Surgery, 2002, 28, 1013-1016.	0.8	101
205	Side-Effects After IPL Photodepilation. Dermatologic Surgery, 2002, 28, 1131-1134.	0.8	116
206	Calcium-fortified milk early in the postmenopausal period delays bone loss in the spine. Evidence-Based Healthcare and Public Health, 2002, 6, 12-13.	0.0	1
207	Use of gonadotropin-releasing hormone analog with tibolone to prevent cyclic attacks of acute intermittent porphyria. Metabolism: Clinical and Experimental, 2001, 50, 995-996.	3.4	6
208	Do women using hormone replacement treatment have less pre-existing cardiovascular risk. Maturitas, 2001, 38, 315-319.	2.4	1
209	A simplified method to quantitate atherosclerosis in the rabbit aorta. Maturitas, 2001, 39, 265-271.	2.4	4
210	Effect of continuous and sequential oral estrogen–progestogen replacement regimens on postmenopausal bone loss: a 2-year prospective study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2001, 99, 261-265.	1.1	6
211	Changes in body mass index around menopause: a population study of Chilean woman. Menopause, 2001, 8, 239-244.	2.0	39
212	A scheme of combined oral contraceptives for women more than 40 years old. Menopause, 2001, 8, 286-289.	2.0	26
213	Mycosis fungoides and pregnancy Oncology Reports, 2001, 8, 197-9.	2.6	15
214	Bone mineral density in young, hypothalamic oligoamenorrheic women treated with oral contraceptives. Journal of reproductive medicine, The, 2001, 46, 875-9.	0.2	36
215	Quality of life after the menopause: a population study. Maturitas, 2000, 34, 17-23.	2.4	229
216	Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas, 2000, 34, 161-168.	2.4	130

#	Article	IF	CITATIONS
217	Sistema cardiovascular y menopausia. Semergen, 2000, 26, 133-135.	0.5	0
218	Transdermal estrogens do not appear to modify the extent of lesional areas of aortic atherosclerosis in oophorectomized rabbits on a cholesterol-rich diet. Atherosclerosis, 2000, 148, 303-308.	0.8	15
219	Letters to the Editor. Menopause, 2000, 7, 417.	2.0	3
220	Dr. Castelo-Branco replies:. Menopause, 2000, 7, 417-418.	2.0	0
221	Long-term postmenopausal hormone replacement therapy effects on bone mass: differences between surgical and spontaneous patients. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1999, 83, 207-211.	1.1	20
222	Effect of menopause and different combined estradiol-progestin regimens on basal and growth hormone-releasing hormone–stimulated serum growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3 levels. Fertility and Sterility, 1999, 71, 261-267.	1.0	43
223	Long-Term Compliance with Estrogen Replacement Therapy in Surgical Postmenopausal Women: Benefits to Bone and Analysis of Factors Associated with Discontinuation. Menopause, 1999, 6, 307-311.	2.0	36
224	Two-Year Prospective and Comparative Study on the Effects of Tibolone on Lipid Pattern, Behavior of Apolipoproteins AI and B. Menopause, 1999, 6, 92???97.	2.0	22
225	SintomatologÃa vasomotora y terapias alternativas a la terapia hormonal de reemplazo. Revista Colombiana De Obstetricia Y Ginecologia, 1999, 50, 107-111.	0.3	Ο
226	Ossein-hydroxyapatite compounds for preventing postmenopausal bone loss. Coadjuvant use with hormone replacement therapy. Journal of reproductive medicine, The, 1999, 44, 241-6.	0.2	5
227	Two-year prospective and comparative study on the effects of tibolone on lipid pattern, behavior of apolipoproteins AI and B. Menopause, 1999, 6, 92-7.	2.0	7
228	Preventing postmenopausal bone loss with ossein-hydroxyapatite compounds. Results of a two-year, prospective trial. Journal of reproductive medicine, The, 1999, 44, 601-5.	0.2	11
229	Isolation and partial characterization of a lectin from Artocarpus incisa L. seeds. Phytochemistry, 1998, 47, 1183-1188.	2.9	50
230	Facial wrinkling in postmenopausal women. Effects of smoking status and hormone replacement therapy. Maturitas, 1998, 29, 75-86.	2.4	95
231	Effects on bone <i>mass</i> of two oral contraceptives containing ethinyl-estradiol and cyproterone acetate or desogestrel: results of a 2-year follow-up. European Journal of Contraception and Reproductive Health Care, 1998, 3, 79-84.	1.5	20
232	Management of Osteoporosis. Drugs and Aging, 1998, 12, 25-32.	2.7	13
233	Posterior Vaginal Wall Repair with Synthetic Absorbable Mesh: A New Technique for an Old Procedure. Journal of Gynecologic Surgery, 1998, 14, 111-117.	0.1	1
234	Normal and gestational diabetic pregnancies. Lipids, lipoproteins and apolipoproteins. Journal of reproductive medicine, The, 1998, 43, 144-8.	0.2	6

#	Article	IF	CITATIONS
235	P-95 Menopause, 1997, 4, 286.	2.0	1
236	P-96 Menopause, 1997, 4, 287.	2.0	0
237	Gonadotropin-releasing hormone analog plus an oral contraceptive containing desogestrel in women with severe hirsutism: Effects on hair, bone, and hormone profile after 1-year use. Metabolism: Clinical and Experimental, 1997, 46, 437-440.	3.4	26
238	The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation. Maturitas, 1996, 23, 307-312.	2.4	68
239	Effects of a long-acting gonadotropin-releasing hormone analog on the pituitary-ovarian-adrenal axis in women with severe hirsutism. Metabolism: Clinical and Experimental, 1996, 45, 24-27.	3.4	23
240	Menstrual history as a determinant of current bone density in young hirsute women. Metabolism: Clinical and Experimental, 1996, 45, 515-518.	3.4	18
241	P022 Evolution of the effect of hormonal replacement therapy in bone mineral density in postmenopausal women. Maturitas, 1996, 27, 122.	2.4	0
242	P023 Bone mineral density in spontaneous and surgically postmenopausal women receiving hormonal replacement therapy. Maturitas, 1996, 27, 123.	2.4	0
243	P190 Long term hormonal replacement therapy (5 years) and lipid profile changes. Maturitas, 1996, 27, 176.	2.4	0
244	Plasma lipids, lipoproteins and apolipoproteins in hirsute women. Acta Obstetricia Et Gynecologica Scandinavica, 1996, 75, 261-265.	2.8	5
245	Effects of progestogen on lipids, lipoproteins and apolipoproteins during transdermal estrogen replacement therapy with and without medroxyprogesterone acetate. Journal of reproductive medicine, The, 1996, 41, 833-8.	0.2	2
246	Is MRI helpful in evaluating the response of cervical cancer to neoadjuvant chemotherapy?. Acta Obstetricia Et Gynecologica Scandinavica, 1995, 74, 467-471.	2.8	4
247	Gynaecological short communication: Compliance with hormone replacement therapy at the menopause. Journal of Obstetrics and Gynaecology, 1995, 15, 204-205.	0.9	9
248	Circulating hormone levels in menopausal women receiving different hormone replacement therapy regimens. A comparison. Journal of reproductive medicine, The, 1995, 40, 556-60.	0.2	19
249	Postmenopausal hormone replacement therapy with low-dose medroxyprogesterone acetate. Endometrium, plasma lipids, lipoproteins and apolipoproteins. Journal of reproductive medicine, The, 1995, 40, 305-11.	0.2	4
250	Primary adenocarcinoma of the endometrium associated with genital tuberculosis. A case report. Journal of reproductive medicine, The, 1995, 40, 673-5.	0.2	8
251	Vaginal Hysterectomy with the Autosuture Stapler. Journal of Gynecologic Surgery, 1994, 10, 21-25.	0.1	2
252	Relationship between skin collagen and bone changes during aging. Maturitas, 1994, 18, 199-206.	2.4	118

#	Article	IF	CITATIONS
253	Solitary Vaginal Metastasis as a Presenting Form of Unsuspected Renal Adenocarcinoma. Gynecologic Oncology, 1994, 52, 260-263.	1.4	12
254	Antagonism of oestrogen-induced prolactin release by medroxyprogesterone acetate. Maturitas, 1994, 20, 145-150.	2.4	1
255	Transvaginal sonography of the endometrium in postmenopausal women: Monitoring the effect of hormone replacement therapy. Maturitas, 1994, 19, 59-65.	2.4	19
256	Umbilical cord torsion; a rare cause of intra-uterine fetal death. Journal of Obstetrics and Gynaecology, 1994, 14, 324-325.	0.9	1
257	Effects of oophorectomy and hormone replacement therapy on pituitary-gonadal function. Maturitas, 1993, 17, 101-111.	2.4	28
258	Pitfalls in mammography screening policy: Breast cancer in a 26-year-old patient. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1993, 48, 141-144.	1.1	0
259	Bone mineral density in surgically postmenopausal women receiving hormonal replacement therapy as assessed by dual photon absorptiometry. Maturitas, 1993, 16, 133-137.	2.4	38
260	Effects of oophorectomy and hormone replacement therapy on plasma lipids. Maturitas, 1993, 17, 113-122.	2.4	10
261	Hormone replacement therapy and changes on pituitary function. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1992, 43, 59-63.	1.1	4
262	The effect of hormone replacement therapy on postmenopausal bone loss. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1992, 44, 131-136.	1.1	41
263	Skin collagen changes related to age and hormone replacement therapy. Maturitas, 1992, 15, 113-119.	2.4	176
264	Clinical efficacy of estradiol transdermal system in the treatment of hot flashes in postmenopausal women. Research and Reports in Transdermal Drug Delivery, 0, , 1.	0.0	1